{"id":"https://openalex.org/W2587549223","doi":"https://doi.org/10.1182/blood.v128.22.4396.4396","title":"Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study","display_name":"Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2587549223","doi":"https://doi.org/10.1182/blood.v128.22.4396.4396","mag":"2587549223"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.4396.4396","doi":"https://doi.org/10.1182/blood.v128.22.4396.4396","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.4396.4396","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051296565","display_name":"Mazyar S. Shadman","orcid":"https://orcid.org/0000-0002-3365-6562","observed_orcids":["https://orcid.org/0000-0002-3365-6562"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mazyar Shadman","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","Division of Medical Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"Division of Medical Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K Gopal","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023180146","display_name":"Oliver W. Press","orcid":"https://orcid.org/0000-0002-3147-8037","observed_orcids":["https://orcid.org/0000-0002-3147-8037"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Oliver Press","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David G. Maloney","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090982367","display_name":"Raya Mawad","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Raya Mawad","raw_affiliation_strings":["Swedish Cancer Institute, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swedish Cancer Institute, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041002170","display_name":"Troy Wadsworth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325808316","display_name":"MultiCare Health System","ror":"https://ror.org/04g0bt697","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325808316"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Troy Wadsworth","raw_affiliation_strings":["Multicare Health Systems, Tacoma, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multicare Health Systems, Tacoma, WA","institution_ids":["https://openalex.org/I1325808316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033701766","display_name":"Trevor W. Dennie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325808316","display_name":"MultiCare Health System","ror":"https://ror.org/04g0bt697","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325808316"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Trevor W. Dennie","raw_affiliation_strings":["Multicare Health Systems, Tacoma, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multicare Health Systems, Tacoma, WA","institution_ids":["https://openalex.org/I1325808316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006396767","display_name":"Karl Schultheiss","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130724","display_name":"Saint Alphonsus Regional Medical Center","ror":"https://ror.org/03r776098","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130724"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Karl Schultheiss","raw_affiliation_strings":["Saint Alphonsus Cancer Care Center, Boise, ID"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint Alphonsus Cancer Care Center, Boise, ID","institution_ids":["https://openalex.org/I4210130724"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077272360","display_name":"Kiarash Kojouri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800475362","display_name":"Skagit Valley Hospital","ror":"https://ror.org/04p3ja862","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800475362"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kiarash Kojouri","raw_affiliation_strings":["Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Skagit Valley Hospital Regional Cancer Care Center, Mount Vernon, WA","institution_ids":["https://openalex.org/I2800475362"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088928406","display_name":"Britt Kammerer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Britt E Kammerer","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040412322","display_name":"John M. Pagel","orcid":"https://orcid.org/0000-0001-5745-8125","observed_orcids":["https://orcid.org/0000-0001-5745-8125","https://orcid.org/0000-0003-2875-4878"]},"institutions":[{"id":"https://openalex.org/I4210093417","display_name":"Swedish Medical Center","ror":"https://ror.org/004jktf35","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210093417","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Pagel","raw_affiliation_strings":["Swedish Medical Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swedish Medical Center, Seattle, WA","institution_ids":["https://openalex.org/I4210093417"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5006396767","https://openalex.org/A5033701766","https://openalex.org/A5041002170","https://openalex.org/A5051296565","https://openalex.org/A5077272360","https://openalex.org/A5088928406","https://openalex.org/A5090982367"],"corresponding_institution_ids":["https://openalex.org/I1325808316","https://openalex.org/I201448701","https://openalex.org/I2800475362","https://openalex.org/I4210089486","https://openalex.org/I4210130724"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.2595,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.64601722,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"128","issue":"22","first_page":"4396","last_page":"4396"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9660000205039978},{"id":"https://openalex.org/keywords/small-lymphocytic-leukemia","display_name":"small lymphocytic leukemia","score":0.9850000143051147},{"id":"https://openalex.org/keywords/fcr-regimen","display_name":"FCR regimen","score":0.6420000195503235},{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":0.9459999799728394},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":1.0},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":1.0},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9549999833106995},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8349999785423279},{"id":"https://openalex.org/keywords/chemoimmunotherapy","display_name":"chemoimmunotherapy","score":0.8299999833106995},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7850000262260437},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8970000147819519},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7440000176429749},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6179999709129333}],"concepts":[{"id":"https://openalex.org/C2776262904","wikidata":"https://www.wikidata.org/wiki/Q905901","display_name":"Vorinostat","level":5,"score":0.8016790747642517},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.7461814284324646},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7052425146102905},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.6453473567962646},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6338503360748291},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.5577726364135742},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49704959988594055},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.4799409508705139},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.45015448331832886},{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.43381187319755554},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3749457895755768},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37129512429237366},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.33697572350502014},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.27664586901664734},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2505161464214325},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.15211448073387146},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.12608954310417175},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08408358693122864},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.4396.4396","doi":"https://doi.org/10.1182/blood.v128.22.4396.4396","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.4396.4396","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2553806602","https://openalex.org/W2564739611","https://openalex.org/W2348637346","https://openalex.org/W2979568374","https://openalex.org/W2080166597","https://openalex.org/W2561133207","https://openalex.org/W2125134816","https://openalex.org/W2556997696","https://openalex.org/W2553030065","https://openalex.org/W2564158403"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Chemoimmunotherapy":[2],"regimens":[3,23,726],"remain":[4],"the":[5,19,60,76,81,97,104,164,196,220,226,291,502,584,642,714],"preferred":[6],"first-line":[7],"treatment":[8,36,70,161,282,294,401,420,710,732],"for":[9,54,59,69,100,142,198,233,362,365,450,522,672,677,709,731],"most":[10],"of":[11,21,34,75,86,125,134,159,208,219,223,241,259,293,341,357,367,399,458,511,540,559,564,575,583,600,604,617,645,668,718,733],"patients":[12,66,149,264,349,351,392,408,417,446,514,543,585,606,638,697],"with":[13,52,57,67,92,475,607,670,675,683,692,721],"CLL/SLL.":[14,734],"Recent":[15],"studies":[16],"have":[17],"demonstrated":[18],"efficacy":[20,33],"maintenance":[22,42,214,227,400,414,419,427,451,678,715,725],"by":[24,527],"improving":[25],"progression-free":[26],"survival":[27,566],"(PFS).":[28],"We":[29],"studied":[30],"safety":[31],"and":[32,41,56,94,118,128,156,179,190,247,300,332,347,359,388,406,488,504,530,532,572,634,654,674,681,687,690,704,724],"a":[35,46,684,728],"protocol":[37],"that":[38,88],"included":[39,309],"induction":[40,55,105,209,342,358,371,472,503,549,590,673,723],"components":[43],"using":[44],"vorinostat,":[45],"histone":[47],"deacetylase":[48],"inhibitor,":[49],"in":[50,297,302,311,315,320,324,329,335,477,481,485,492],"combination":[51],"FCR":[53,93,107,671],"rituximab":[58,119,236,676],"maintenance.":[61,363,555],"Methods:":[62],"Previously":[63],"untreated":[64],"CLL/SLL":[65],"indication":[68],"were":[71,210,269,360,373,448,520,626,706],"eligible.":[72],"Primary":[73],"objective":[74],"Phase":[77],"I":[78],"part":[79],"was":[80,96,137,169,185,193,237,249,273,283,295,344,473,507,545,567,577,661,679],"maximum":[82],"tolerated":[83],"dose":[84,165,173,187,240],"(MTD)":[85],"vorinostat":[87,151,168,248,669],"could":[89],"be":[90],"combined":[91],"PFS":[95,576,691],"primary":[98],"endpoint":[99],"phase":[101,199],"II.":[102,200],"In":[103,145,163,225],"phase,":[106,167,228],"(fludarabine":[108],"25":[109],"mg/m2":[110,115,121,130,243],"days":[111,116,141,154,157,257],"1-3,":[112],"cyclophosphamide":[113],"250":[114],"1-3":[117],"375":[120],"on":[122,131,153,244,256],"day":[123,132,245],"1":[124,127,133,246,397,493,505],"cycle":[126,222,398],"500":[129,242],"subsequent":[135],"cycles)":[136],"given":[138,170,229,238,250],"every":[139,230],"28":[140],"6":[143,336,345,605],"cycles.":[144,415],"addition":[146],"to":[147,212,281,430,551,659],"FCR,":[148],"received":[150,203,394],"orally":[152],"1-5":[155],"8-12":[158],"each":[160,260],"cycle.":[162,261],"finding":[166],"at":[171,204,239,251,290,353,395],"3":[172,217,231,325,603],"levels:":[174],"200":[175],"mg,":[176],"300":[177],"mg":[178,181,192,253],"400":[180,191,252],"PO":[182,254],"daily.":[183],"There":[184],"no":[186,693],"limiting":[188],"toxicity":[189,378],"chosen":[194],"as":[195],"MTD":[197],"Patients":[201],"who":[202,515,544,586,698],"least":[205,354,396],"4":[206,321,355,370,482,637],"cycles":[207,343,356,372],"eligible":[211,361,449],"receive":[213,424,455],"beginning":[215],"within":[216],"months":[218,232,285,599,619,663],"last":[221],"FCR.":[224],"8":[234,412,426],"cycles,":[235],"daily":[255],"1-14":[258],"Results:":[262],"40":[263,618],"(CLL":[265],"32,":[266],"SLL":[267],"8)":[268],"treated.":[270],"Median":[271,277,339,657],"age":[272],"58":[274],"years":[275],"(36-72).":[276],"time":[278,292,658],"from":[279],"diagnosis":[280],"27":[284],"(0":[286],"-102).":[287],"Rai":[288],"stage":[289],"I/II":[296],"23":[298,512],"(60%)":[299],"III/IV":[301],"17":[303],"(40%)":[304,409],"patients.":[305,338],"Cytogenetic":[306],"(CG)":[307],"abnormalities":[308,334,630],"del17p":[310],"2":[312,316,486,541],"(5%),":[313,317],"del11q":[314],"trisomy":[318],"12":[319],"(10%),":[322],"del13q":[323],"(7.5%),":[326],"normal":[327],"CG":[328],"14":[330],"(35%)":[331],"other":[333,442],"(15%)":[337,447],"number":[340],"(1-6)":[346],"33":[348],"(83%)":[350],"finished":[352,410],"Reasons":[364],"delivery":[366],"less":[368],"than":[369],"patient":[374,433,465,496],"preference":[375,434,466],"(2),":[376],"GI":[377],"(1),":[379,381,384,437,648,650],"thrombocytopenia":[380],"pulmonary":[382],"emboli":[383],"progressive":[385,499],"disease":[386,490,500,525,594,612,646],"(1)":[387,440,463,653],"sepsis":[389,649],"(1).":[390,656],"Twenty-six":[391],"(65%)":[393],"(median":[402],"8;":[403],"range,":[404],"1-8)":[405],"15":[407],"all":[411,425],"planned":[413],"Eleven":[416],"started":[418],"but":[421,452],"did":[422,453],"not":[423,454,508],"courses":[428],"due":[429],"neutropenia":[431],"(3),":[432,435,461],"infections":[436,705],"insurance":[438],"issues":[439],"or":[441,464,609],"reasons":[443,708],"(3).":[444],"Six":[445],"it":[456],"because":[457,644],"hematologic":[459,627],"toxicities":[460,625],"infection":[462,652],"(2).":[467],"Overall":[468],"response":[469],"rate":[470],"after":[471,518,548,554,589,596,701],"91%":[474],"CR":[476,517,542,588,700],"26":[478],"(74%),":[479],"PR":[480,608],"(11%),":[483],"nPR":[484,610],"(6%)":[487],"stable":[489],"(SD)":[491],"(3%).":[494],"One":[495,539],"(3%)":[497,506],"had":[498,535,593,611],"during":[501,641,713],"evaluable.":[509],"Twenty-one":[510],"(88%)":[513],"achieved":[516,587,699],"induction,":[519],"tested":[521],"minimal":[523],"residual":[524],"(MRD)":[526],"flow":[528],"cytometry":[529],"cytogenetics":[531],"21":[533],"(91%)":[534],"negative":[536,553],"MRD":[537,546,552],"status.":[538],"positive":[547],"converted":[550],"After":[556],"median":[557,597,616],"follow-up":[558,601,643],"42":[560],"months,":[561],"5-year":[562,573],"estimate":[563,574],"overall":[565],"90%":[568],"(95%":[569,579],"CI":[570,580],"75%-96%)":[571],"72%":[578],"51%-85%).":[581],"None":[582],"(n=26;":[591],"74%)":[592],"progression":[595,613,647],"46":[598],"while":[602],"which":[614],"occurred":[615],"(29-51).":[620],"Most":[621],"common":[622],"grade":[623],"3-4":[624],"(36%),":[628],"electrolyte":[629],"(9%),":[631],"gastrointestinal":[632],"(8%)":[633],"cardiovascular":[635],"(6%).":[636],"(10%)":[639],"died":[640],"fungal":[651],"suicide":[655],"death":[660],"9.5":[662],"(5":[664],"-20).":[665],"Conclusion:":[666],"Combination":[667,717],"feasible":[680],"effective":[682],"high":[685],"ORR":[686],"long":[688],"OS":[689],"relapses":[694],"observed":[695],"among":[696],"induction.":[702],"Cytopenias":[703],"main":[707],"discontinuation":[711],"especially":[712],"phase.":[716],"novel":[719],"agents":[720],"conventional":[722],"is":[727],"promising":[729],"strategy":[730],"Disclosures":[735],"Shadman:":[736],"Gilead:":[737],"Honoraria,":[738,748,771],"Research":[739,742,745,749,758,772,778,782],"Funding;":[740,743,746,783],"Emergent:":[741],"Acerta:":[744],"Pharmacyclics:":[747],"Funding.":[750,773,779],"Gopal:Paid":[751],"Consultancy-":[752],"Gilead,":[753,760],"Janssen,":[754,761],"Seattle":[755,768],"Genetics,":[756],"Spectrum,":[757,767],"funding-":[759],"Pfizer,":[762],"BMS,":[763],"Merck,":[764],"Teva,":[765],"Takeda,":[766],"Genetics:":[769],"Consultancy,":[770,777,785],"Press:Roche":[774],"/":[775],"Genentech:":[776],"Maloney:Juno":[780],"Therapeutics:":[781],"Genentech/Roche:":[784],"Honoraria.":[786]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-17T00:00:00"}